Rituximab for patients with nephrotic syndrome

The Lancet

Volumn 385, Issue 9964, 2015, Pages 225-

  Keijzer Veen, Mandy G ^b   Hebert, Diane ^a   Parekh, Rulan S ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MYCOPHENOLIC ACID; RITUXIMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

COHORT ANALYSIS; DRUG SAFETY; FOLLOW UP; HUMAN; LETTER; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME;

EID: 84921275530     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60049-6     Document Type: Letter

References (5)

1. K Iijima, M Sako, K Nozu et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 2014 1273 1281
2. N Hussain, JA Zello, J Vasilevska-Ristovska et al. The rationale and design of insight into nephrotic syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome BMC Nephrol 14 2013 25
3. DB Rubin Estimating causal effects from large data sets using propensity scores Ann Intern Med 127 1997 757 763
4. DS Ardelean, T Gonska, S Wires et al. Severe ulcerative colitis after rituximab therapy Pediatrics 126 2010 e243 e246
5. M Sato, S Ito, M Ogura, K Kamei Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome Pediatr Nephrol 29 2014 1373 1379